Details for Patent: 8,846,074
✉ Email this page to a colleague
Which drugs does patent 8,846,074 protect, and when does it expire?
Patent 8,846,074 protects KYNMOBI and is included in one NDA.
This patent has thirty-five patent family members in twenty countries.
Summary for Patent: 8,846,074
| Title: | Sublingual films |
| Abstract: | The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith. |
| Inventor(s): | Bryson; Nathan John (Toronto, CA), Giovinazzo; Anthony John (Oakville, CA), Barnhart; Scott David (York, PA), Koons; Michael Clinton (York, PA) |
| Assignee: | Cynapsus Therapeutics, Inc. (Toronto, CA) ARx, LLC (Glen Rock, PA) |
| Application Number: | 13/858,638 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 8,846,074
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-005 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,846,074
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011343429 | ⤷ Try a Trial | |||
| Australia | 2017200331 | ⤷ Try a Trial | |||
| Australia | 2019200138 | ⤷ Try a Trial | |||
| Brazil | 112013015204 | ⤷ Try a Trial | |||
| Canada | 2821756 | ⤷ Try a Trial | |||
| Canada | 3115370 | ⤷ Try a Trial | |||
| Canada | 3115378 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
